Purple Biotech Ltd
NASDAQ:PPBT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PPBT's latest stock split occurred on Mar 2, 2026
The company executed a 1-for-10 stock split, meaning that for every 10 shares held, investors received 1 new share.
Before the split, PPBT traded at 4.42 per share. Afterward, the share price was about 4.25.
The adjusted shares began trading on Mar 2, 2026. This was PPBT's 3rd stock split, following the previous one in Sep 17, 2024.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 21, 2026
|
W
|
WellCell Holdings Co Ltd
HKEX:2477
|
4-for-1
x4
|
111.28 27.82 HKD | 5.06 5.06 HKD |
|
Apr 21, 2026
|
|
Canon Electronics Inc
TSE:7739
|
1-for-6235122
/6235122
|
3635 3635 JPY | N/A |
|
Apr 20, 2026
|
|
AnaptysBio Inc
NASDAQ:ANAB
|
15-for-10
x1.5
|
67.5101 45.0067 USD | 50.95 50.95 USD |
|
Apr 20, 2026
|
|
ConnectM Technology Solutions Inc
NASDAQ:CNTM
|
1-for-32
/32
|
0.265 8.48 USD | 8.48 8.48 USD |
|
Apr 20, 2026
|
|
Eshallgo Inc
NASDAQ:EHGO
|
1-for-16
/16
|
0.1421 2.2736 USD | 2.5 2.5 USD |
7739
ANAB
CNTM
EHGO
Purple Biotech Ltd
Glance View
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
